The Latest Breaking News on Pharma

Renowned biopharmaceutical company AbbVie (ABBV) continued its business momentum in the second quarter with considerable progress for its new products and indications. Moreover, the company is well-positioned to benefit from significant advances across its pipeline. Given its diversified business model, strong financials, high profitability, discounted valuation, and solid growth prospects,…

Despite the market volatility and odds of a recession, the pharma industry is well-positioned to grow due to the aging global population and the increasing chronic diseases. Therefore, investing in quality pharma stocks Pfizer (PFE) and Merck & Co. (MRK) could be wise. Read more.

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

The Community Anti-Drug Coalitions of America (CADCA), which is fighting against federal cannabis legalization, recently removed a page on its website disclosing its partners.

Johnson worried that bill allowing Medicare to negotiate costs is "punishing the pharmaceutical industry"

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S.

Blood products and vaccines supplier CSL has reported a six per cent fall in annual profit and is tipping a slightly better earnings performance in 2022/23.

The legislation has been a year in the making, with tense negotiations leading to a narrower spending package that focuses on climate investments and health care costs.

A new FDA rule allows adults with perceived mild to moderate hearing loss to buy hearing aids over the counter. Efforts to make them more affordable and accessible have been in the works for years.